CRDF Stock Summary and Trading Ideas (Cardiff Oncology | NASDAQ:CRDF)

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

What symbol and exchange does Cardiff Oncology shares trade?

Cardiff Oncology trades on the NASDAQ stock market under the symbol CRDF.

What is Cardiff Oncology stock price doing today?

As of March 5, 2026, CRDF stock price declined to $1.87 with 540,774 million shares trading.

What is Cardiff Oncology's Beta?

CRDF has a beta of 1.48, meaning it tends to be more sensitive to market movements. CRDF has a correlation of 0.07 to the broad based SPY ETF.

How much is Cardiff Oncology worth?

CRDF has a market cap of $124.40 million. This is considered a Micro Cap stock.

How much money does Cardiff Oncology make?

Last quarter Cardiff Oncology reported $243,000 in Revenue and -$.11 earnings per share. This beat revenue expectation by $128,900 and exceeded earnings estimates by $.08.

What is the highest and lowest price Cardiff Oncology traded in the last 3 year period?

In the last 3 years, CRDF traded as high as $6.42 and as low as $.94.

What are the top ETFs holding Cardiff Oncology?

The top ETF exchange traded funds that CRDF belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

Is Cardiff Oncology (CRDF) a good investment?

CRDF has underperformed the market in the last year with a return of -49.9%, while the SPY ETF gained +19.4%. In the last 3 month period, CRDF fell short of the market, returning -13.4%, while SPY returned -0.2%. However, in the most recent 2 weeks CRDF has outperformed the stock market by returning +19.9%, while SPY returned -0.7%.

What are the support and resistance levels for Cardiff Oncology (CRDF)?

CRDF support price is $1.89 and resistance is $2.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRDF shares will trade within this expected range on the day.